ArticleACS medicinal chemistry letters2025
Targeted Treatment of Cancer by Using Conjugate Compounds with Poly(ADP-ribose) Polymerase (PARP) Inhibitors.
Article in ACS medicinal chemistry letters, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- The Promise of Selective PARP1 Inhibitors in Cancer Therapy.ACS medicinal chemistry letters · 2025Article
- Novel Isoindolinone-Containing PARP Inhibitors: Synthesis and Therapeutic Applications in CNS Cancer Treatment.ACS medicinal chemistry letters · 2025Article
- Preparation of Novel PARP1 Inhibitors and Their Use in Cancer Treatment.ACS medicinal chemistry letters · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
This patent describes a novel therapeutic strategy involving conjugate compounds that integrate a poly-(ADP-ribose) polymerase (PARP) inhibitor moiety with a disease-targeting ligand, offering a dual-function approach for the treatment of cancer. These conjugates are designed to enhance the efficacy of targeted radionuclide therapies by selectively delivering PARP inhibition to tumor cells, thereby disrupting DNA repair mechanisms and increasing cancer cell susceptibility to DNA damage-induced cytotoxicity.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.